| Literature DB >> 36003314 |
Mehrdad Karajizadeh1, Soheil Hassanipour2, Roxana Sharifian3, Fatemeh Tajbakhsh3, Hamid Reza Saeidnia4.
Abstract
Introduction: Clinical decision support systems (CDSSs) play an important role in summarizing the best clinical practices, thereby promoting high standards of care in specific medical fields. These systems can serve as tools for gaining knowledge and mediating between clinical guidelines and physicians thereby providing the right information to the right person at the right time. Objective: This review aims to evaluate the effect of CDSSs on adherence to guidelines for venous thromboembolism (VTE) prophylaxis and VTE events compared to routine care without CDSSs in non-surgical patients.Entities:
Keywords: Decision support systems; non-surgical patients; prophylaxis; venous thromboembolism
Year: 2022 PMID: 36003314 PMCID: PMC9393686 DOI: 10.1177/20552076221118828
Source DB: PubMed Journal: Digit Health ISSN: 2055-2076
Search strategies used in the different databases.
| Databases | Search items |
|---|---|
| PubMed | (“Decision Support Systems, Clinical” OR “Computerized clinical decision support systems” OR “Medical Records Systems, Computerized”) AND (“Risk Factors” OR “Risk Adjustment” OR “Risk Management” OR “Risk Assessment”) AND (“Venous Thromboembolism/prevention and control OR “Anticoagulants”) |
| Ovid | (“Decision Support Systems, Clinical” OR “computerized clinical decision support systems” OR “Medical Records Systems, Computerized”) AND (“Risk Factors” OR “Risk Adjustment “OR “Risk Management “OR “Risk Assessment”) AND (“Treatment Outcome”) AND (“Venous Thromboembolism” OR “Anticoagulants”) |
| EMBASE | Decision support systems/ and (risk factor or risk management or risk adjustment) and (treatment outcome)- remove abstracts |
| Cochrane | Venous thromboembolism and prophylaxis |
| Scopus | (“Decision Support Systems, Clinical” OR “Computerized clinical decision support systems” OR “Medical Records Systems, Computerized”) AND (Thromboembolism OR Venous thrombosis) |
| Clinicaltrials.gov | Clinical decision support and venous thromboembolism |
| ISI web of science | Title: (clinical decision support and venous thromboembolism) |
Figure 1.Summary of results of search and screening of the studies.
Newcastle–Ottawa scale (NOS) scores and risk of bias of the studies.
|
| |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Selection | Comparability | Outcome | Total | ||||||
| Representativeness of the exposed cohort | Selection of the non-exposed cohort | Ascertainment of exposure | Demonstration that outcome was not KNOWN at the start of the study | Comparability of groups on the basis of analysis | Assessment of outcome | Follow-up being long enough for outcomes | Adequacy of follow up of cohorts | ||
| Study | Variety of nonsurgical patients (with CDSS) | Variety of nonsurgical patients (without CDSS) | CDSS | Stated in articles | Controlled for VTE risk factors between groups | Blinded or record linkage | Three months | 90%–100% complete follow up | |
| Spirk et al., 2017
| * | * | * | * | ** | | * | * | 8 |
| Mathers et al., 2017
| * | * | * | * | ** | | * | * | 8 |
| Eijgenraam et al., 2015
| * | * | * | * | * | | * | * | 7 |
| Amland et al., 2015
| * | * | * | * | ** | | * | * | 8 |
| Fuzinatto et al., 2013
| * | * | * | * | ** | | * | * | 8 |
| Bhalla et al., 2012
| * | * | * | * | * | | * | * | 7 |
| Umscheid et al., 2012
| * | * | * | * | * | | * | * | 7 |
| Mitchell et al., 2012
| * | * | * | * | * | | * | * | 7 |
| MaCauley et al., 2012
| * | * | * | * | ** | | * | * | 8 |
| Galanter et al.,2010
| * | * | * | * | ** | | * | * | 8 |
| Piazza et al., 2010
| * | * | * | * | ** | | * | * | 8 |
| Kucher et al., 2005
| * | * | * | * | ** | | * | * | 8 |
Characteristics of the randomized control trial.
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
| SPIRK et al., 2017
|
|
|
|
|
|
|
| Piazza et al., 2010
|
|
|
|
|
|
|
| Kucher et al., 2005
|
|
|
|
|
|
|
Characteristics of the observational studies.
| Outcomes reported | Intervention | Guideline | Risk assessment tools | Time scale | Setting and participants | Study design | Country | References |
|---|---|---|---|---|---|---|---|---|
| Proportion of IBD patients receiving pharmacologic VTE prophylaxis | Electronic alert | ACCP 2008 | During hospitalization, before and after electronic alert system implementation, (between January 1, 2007 and December 31, 2012) | 576 hospitalized IBD patients in PSHMC | Retrospective cohort study (pre-post implementation test) | USA | Mathers et al., 2017
| |
| The group in need of antithrombotic measures according to the MUMC protocol | Clinical decision support on adherence to thrombosis prophylaxis guidelines | ACCP 2008 | Padua Prediction Score | 24h after hospitalization, patients selected 3 days before and 2 days after the introduction(days were on different dates, not in a row) | Non-surgical patients, 64 medical patients before the introduction of the CDSS and 64 patients after the introduction | Pre-post implementation | The Netherlands | Eijgenraam et al., 2015
|
| VTE per 1000 patient days, odds ratios for differences VTE Advisor Alert and Notify Flag | CDSS to prevent venous thromboembolism | ACCP 2008 | Observation window spanned 6 months for each cohort | Adult inpatients, urban tertiary and level 1 trauma center, 45,046 hospitalizations representing 171,753 patient days | Pre-posttest, longitudinal, cohort design (retrospective for pretest-prospective for posttest) | USA | Amland et al., 2015
| |
| Appropriate venous thromboembolism prophylaxis | Creation of a CDSS and proportion of patients receiving appropriate VTE prophylaxis | ACCP 2008 | 3 months before and 2 months after the implementation | Clinical and surgical patients, 262 patients before and 261 patients after the implementation | Cross-sectional pre-post test | Brazil. | Fuzinatto et al., 2013
| |
| VTE prophylaxis ordering, pharmacological VTE prophylaxis ordering, and hospital-acquired VTE | Computerized decision support application to improve VTE prophylaxis | 6-month periods before and after the implementation | Adult inpatients on hospital medicine and non-medicine services in academic medical centers, whose discharge volume was 36,500 as the population of focus for the improvement effort | Observational cohort study(pre-posttest) | USA | Bhalla et al., 2013
| ||
| Estimated increase in VTE prophylaxis use | Electronic admission order set and VTE risk assessment and prophylaxis | (between April 2007 and May 2010)12 months prior to the first CDS intervention; the second period included admissions between the first and second versions of the CDS intervention; the third period included admissions in the 8 months following the implementation | Three acute care teaching hospitals, all adults admitted to an acute care inpatient service, 223,062 inpatients | Quasi-experimental study(pre-posttest) | USA | Umscheid et al., 2012
| ||
| Rates of prophylaxis | An electronic reminder was added to the electronic medical record admission note, prophylaxis, VTE, and bleeding rates | ACCP 2008 | 6-month period before and after the implementation system | Adult medical and surgical patients, 2888 patients before and 2350 patients after the intervention | Pre-post test | USA | Mitchell et al., 2012
| |
| Received prophylaxis recommendation, VTE events at 30 days | CDSS tool for VTE risk stratification and prophylaxis | During a 13-month period, a 4-month pre-implementation cohort and a 9-month post-implementation cohort | Medical and surgical patients who would have been deemed “low-risk”, 1322 patients’ pre-implementation and 3347 patients post-implementation | Pre-post test | USA | MaCauley et al., 2012
| ||
| Prophylactic measures | Computer alert program and prescription of prophylaxis | 90-day between the two Cohorts, 22 months | Patients at least 18 years of age who were hospitalized on medical and surgical services (880 patients), one-screen alert (n = 425), and three-screen alert (n = 455) | Control and intervention cohorts(pre-posttest) | USA | Fiumara et al., 2010
|
Appropriateness of venous thromboembolism prophylaxis in non-surgical patients.
|
|
| |||
|---|---|---|---|---|
|
|
|
|
| |
| Eijgenraam et al., 2015
| 1.000 | 0.494 | 2.025 | 1.000 |
| Fuzinatto et al., 2013
| 1.600 | 1.132 | 2.260 | 0.008 |
| Mitchell et al., 2012
| 2.005 | 1.795 | 2.239 | 0.000 |
| Total | 1.692 | 1.254 | 2.228 | 0.001 |
Figure 2.Appropriateness of venous thromboembolism prophylaxis in non-surgical patients.
Receive venous thromboembolism prophylaxis in non-surgical patients.
|
|
| |||
|---|---|---|---|---|
|
|
|
|
| |
| Mathers et al., 2017
| 4.827 | 2.768 | 8.429 | 0.000 |
| Eijgenraam et al., 2015
| 1.207 | 0.603 | 2.417 | 0.596 |
| Bhalla et al., 2012
| 2.813 | 2.667 | 2.966 | 0.000 |
| Umscheid et al., 2012
| 1.969 | 1.900 | 2.041 | 0.000 |
| Mitchell et al., 2012
| 1.514 | 1.341 | 1.710 | 0.000 |
| MaCauley et al., 2012
| 1.381 | 1.200 | 1.591 | 0.000 |
| Galanter et al., 2010
| 2.306 | 2.161 | 2.461 | 0.000 |
| Total | 2.023 | 1.666 | 2.457 | 0.000 |
The incidence of venous thromboembolism in non-surgical patients.
|
|
| |||
|---|---|---|---|---|
|
|
|
|
| |
| Amland et al., 2015
| 0.468 | 0.244 | 0.894 | 0.022 |
| Umscheid et al., 2012
| 0.790 | 0.757 | 0.824 | 0.000 |
| Mitchell et al., 2012
| 0.748 | 0.344 | 1.624 | 0.463 |
| MaCauley et al., 2012
| 0.459 | 0.212 | 0.994 | 0.048 |
| Galanter et al., 2010
| 0.598 | 0.383 | 0.934 | 0.024 |
| Total | 0.682 | 0.545 | 0.855 | 0.001 |